Sodium-Glucose Cotransporter 2 Inhibition in Diabetic Kidney Disease
Summary
Sodium-glucose cotransporter 2 (SGLT2) inhibitors represent a transformative class of therapy for diabetic kidney disease, acting in the renal proximal tubule to block reabsorption of filtered glucose and promote glycosuria. Beyond improvements in glycaemic control, these agents confer direct renal benefits by reducing intraglomerular pressure, attenuating glomerular hyperfiltration and moderating maladaptive haemodynamics. Secondary mechanisms include modulation of tubular energy metabolism, reduction of oxidative stress and mitigation of low-grade inflammation and fibrosis. Clinical data have demonstrated consistent slowing of albuminuria progression, preservation of estimated glomerular filtration rate and reduced incidence of acute kidney injury across a spectrum of diabetic populations, often independent of baseline glycaemic status or background therapy. The global impact of SGLT2 inhibition extends to improved cardiovascular outcomes and reduced healthcare burden from end-stage kidney disease. Current research seeks to refine patient stratification, elucidate molecular targets such as hypoxia-inducible pathways and explore combinatorial regimens with renin–angiotensin system blockers. As clinical trials embed SGLT2 inhibitors into standard of care, understanding their pleiotropic actions on renal physiology and long-term prognosis remains a priority for clinicians and researchers alike.
Research from Nature Portfolio
No recent Nature Portfolio content available.
Sodium-Glucose Cotransporter 2 Inhibition in Diabetic Kidney Disease publication trend
The graph below shows the total number of articles in sodium-glucose cotransporter 2 inhibition in diabetic kidney disease across all publications each year (not limited to Nature Index journals).
Technical terms
Sodium-glucose cotransporter 2 (SGLT2): A membrane protein in renal proximal tubule cells responsible for reabsorbing the majority of filtered glucose.
Glomerular hyperfiltration: An early increase in single-nephron filtration rate that can lead to long-term glomerular injury in diabetes.
Albuminuria: The presence of albumin in the urine, reflecting glomerular barrier dysfunction and a marker of kidney damage.
Tubulointerstitial fibrosis: Accumulation of extracellular matrix in the renal interstitium and tubules, contributing to progressive loss of kidney function.
References
- SGLT2 Inhibitors: The Sweet Success for Kidneys. Annual Review of Medicine (2023).
- SGLT2 Protein Expression Is Increased in Human Diabetic Nephropathy SGLT2 PROTEIN INHIBITION DECREASES RENAL LIPID ACCUMULATION, INFLAMMATION, AND THE DEVELOPMENT OF NEPHROPATHY IN DIABETIC MICE*. Journal of Biological Chemistry (2017).
- SGLT2 Inhibitors as a Therapeutic Option for Diabetic Nephropathy. International Journal of Molecular Sciences (2017).
- Hypoxia-inducible factor-1α is the therapeutic target of the SGLT2 inhibitor for diabetic nephropathy. Scientific Reports (2019).
About these summaries
This Nature Research Intelligence Topic summary is created with the cited references and a large language model. We take care to ground generated text with facts, and have systems in place to gain human feedback on the overall quality of the process in line with our AI principles. We strive to create accurate and useful summaries for people unfamiliar with the research topic and that supports this goal. These pages are a beta release and will be updated as we learn how best to help people gain value from a research topic summary.
Turn complex research questions into confident strategic decisions
When you're under pressure to set direction, justify investment, or understand your competitive position, you need more than raw data — you need trusted insights you can act on.
Benchmark your performance against global peers using robust, methodologically sound analysis.
Combine quantitative metrics with qualitative expert insight to uncover strengths, gaps and emerging opportunities.
Gain tailored, decision-ready recommendations aligned to your strategic priorities.
Talk to us to learn more about our data dashboards and bespoke strategy reports.
Grow research skills, confidence and careers with training built for every stage of the research lifecycle.
Developed with Nature Portfolio journal Editors and internationally renowned experts. Discover three ways to learn:
Self-paced, online courses in convenient bite-sized units, covering key skills across scientific writing, publishing, grant writing, data analysis, and more.
Expert trainer-led workshops with hands-on exercises and real-time feedback across core research skills, delivered via interactive group sessions.
Editor-led workshops combining core principles in writing and publishing, personalised 1:1 feedback from Nature Portfolio Editors and hands-on exercises.
Explore course catalogues and workshop agendas, enquire about the options or request institutional pricing.